U.S. Markets closed

OraSure Technologies, Inc. (OSUR)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
18.00-0.36 (-1.96%)
At close: 4:00PM EDT
People also watch
QDELTRIBPGNXRTIXPTIE

OraSure Technologies, Inc.

220 East First Street
Bethlehem, PA 18015
United States
610-882-1820
http://www.orasure.com

SectorHealthcare
IndustryMedical Instruments & Supplies
Full Time Employees325

Key Executives

NameTitlePayExercisedAge
Mr. Douglas A. MichelsChief Exec. Officer, Pres and Director1.26M91.09k60
Mr. Ronald H. SpairChief Financial Officer, Chief Operating Officer and Director846.14kN/A61
Dr. Michael Reed Ph.D.Chief Science Officer and Sr. VP of R&D504.45kN/A48
Mr. Jack E. JerrettSr. VP, Gen. Counsel and Sec.505.92k156.15k58
Mr. Anthony Zezzo IIExec. VP of Marketing & Sales580.57kN/A63
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Its principal products include OraQuick ADVANCE HIV-1/2, OraQuick HIV–1/2, OraQuick HIV self-test, OraQuick HCV, OraQuick In-Home HIV test, OraQuick Ebola, OraQuick Zika, OraSure QuickFlu rapid flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect, OMNIgene DISCOVER, Performagene LIVESTOCK and Oragene ANIMAL, OMNIgene GUT, OMNIgene SPUTUM, PrepIT MAX, OMNIgene VAGINAL, OMNIgene ORAL, PrepIT, Intercept, MICRO-PLATE DOA assays, Intercept i2, homogeneous DOA assays, and professional and over-the-counter cryosurgical systems. In addition, the company offers oral fluid collection devices to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, pharmacogenomics, personalized medicine, microbiome and animal genetics, and academic research markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, distributors, government agencies, physicians’ offices, commercial and industrial entities, retail pharmacies, mass merchandisers, and consumers. OraSure Technologies, Inc. was founded in 1979 and is based in Bethlehem, Pennsylvania.

Corporate Governance

OraSure Technologies, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 4. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 8; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.